OncoNano Medicine, Inc.   Report issue

For profit Phase 2
Founded: Dallas TX United States (2014)

Organization Overview

First Clinical Trial
2019
NCT03735680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OncoNano Medicine, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

indocyanine green (ic-green) (1 trial)

pegsitacianine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2